Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neuren Pharmaceuticals Limited ( (AU:NEU) ) has provided an announcement.
Neuren Pharmaceuticals has disclosed a change in the shareholding of director Joseph Basile, who increased his direct interest in the company through an on-market trade. Basile acquired 12,300 ordinary shares on 5 March 2026 at $12.34 per share, lifting his total holding to 48,206 shares, with 36,800 held directly and 11,406 held indirectly via his self-managed superannuation fund.
The purchase, valued at $151,782, signals a higher personal financial commitment by the director to Neuren and may be viewed by investors as a vote of confidence in the company’s prospects. The company confirmed the transaction did not occur during a closed trading period, and there were no changes to any director-related contracts associated with this notice.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$22.00 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited is a biopharmaceutical company listed on the ASX, focused on developing and commercializing therapies in the pharmaceuticals sector. The company’s securities are ordinary shares, and its investor base includes both direct shareholders and those holding interests through structures such as self-managed superannuation funds.
Average Trading Volume: 408,579
Technical Sentiment Signal: Sell
Current Market Cap: A$1.52B
Learn more about NEU stock on TipRanks’ Stock Analysis page.